The FDA is concerned about heart problems following issues related to rival Bristol-Myers' similar treatment for hepatitis C.
While Romney's VP pick may be a good talking point this week, investors are still watching Europe.
This lack of liquidity has led to a whole new set of rules.
Shares of a 3% dividend yield, solid blue-chip drug company are valuable in shaky economic times.
Stocks slide following the European Central Bank president's press conference.
A slew of recent M&A activity may give hope to investment banks.
The transaction also includes a $3.4 billion payment from AstraZeneca as the big drug companies try to replace lost sales from products with generic competition.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The offering could become the second-biggest this year if underwriters exercise an option to buy more shares.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.